Krumholz, Harlan M.
Ross, Joseph S.
Article History
First Online: 22 January 2018
Competing interests
: J.S.R. declares funding from the NIH. He has not acted as an advisor for the NIH and was not involved in the planning and implementation of the NIH clinical trials policy. H.M.K has received NIH funding and was previously on the advisory committee to the director of the NIH for several years. H.M.K was not involved in the planning and implementation of the NIH clinical trials policy. In the past 36 months, H.M.K and J.S.R. have had research agreements with Medtronic and Johnson & Johnson (Janssen), through Yale University, to develop methods of clinical trial data sharing. H.M.K chairs a cardiac scientific advisory board for UnitedHealth; is a participant/participant representative of the IBM Watson Health Life Sciences Board; is a member of the advisory boards of Element Science and Aetna; and is the founder of Hugo, a personal health information platform. J.S.R. has received support through Yale University from Medtronic, Inc. and the Food and Drug Administration (FDA), from the FDA to establish Yale-Mayo Clinic Center for Excellence in Regulatory Science and Innovation (CERSI) programme, from the Blue Cross Blue Shield Association, from the Centers of Medicare and Medicaid Services (CMS) to develop and maintain performance measures that are used for public reporting, from the Agency for Healthcare Research and Quality, from the National Heart, Lung and Blood Institute of the NIH, and from the Laura and John Arnold Foundation to establish the Good Pharma Scorecard at Bioethics International and to establish the Collaboration for Research Integrity and Transparency (CRIT) at Yale.
Free to read: This content has been made available to all.